Li, Charles H. http://orcid.org/0000-0001-8091-6112
Coffey, Eliot L. http://orcid.org/0000-0002-6579-6527
Dall’Agnese, Alessandra
Hannett, Nancy M.
Tang, Xin
Henninger, Jonathan E. http://orcid.org/0000-0002-9604-2007
Platt, Jesse M.
Oksuz, Ozgur
Zamudio, Alicia V.
Afeyan, Lena K.
Schuijers, Jurian
Liu, X. Shawn
Markoulaki, Styliani
Lungjangwa, Tenzin
LeRoy, Gary
Svoboda, Devon S.
Wogram, Emile
Lee, Tong Ihn
Jaenisch, Rudolf http://orcid.org/0000-0002-2540-7099
Young, Richard A. http://orcid.org/0000-0001-8855-8647
Article History
Received: 31 July 2019
Accepted: 15 July 2020
First Online: 22 July 2020
Competing interests
: R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics. R.J. is an advisor/co-founder of Fate Therapeutics, Fulcrum Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics. T.I.L. is a shareholder of Syros Pharmaceuticals and a consultant to Camp4 Therapeutics. All other authors declare no competing interests.